Keyphrases
Chronic Lymphocytic Leukemia
100%
Ibrutinib
41%
Chlorambucil
25%
Leukemia Patients
24%
Obinutuzumab
23%
Fixation Duration
22%
Progression-free Survival
22%
Overall Survival
20%
Humoral Response
18%
BNT162b2 Vaccine
18%
Venetoclax
18%
Positron Emission Tomography-computed Tomography (PET-CT)
17%
Relapsed or Refractory
17%
Rituximab
17%
Richter Transformation
17%
Overall Response Rate
17%
COVID-19 Vaccine
16%
Minimal Residual Disease
16%
Chronic Lymphocytic Leukemia Cells
16%
Vaccine Dose
15%
BNT162b2
15%
COVID-19
15%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
14%
Non-Hodgkin Lymphoma
14%
Acute Myeloid Leukemia
14%
Relapsed or Refractory Acute Myeloid Leukemia
14%
Complete Response
14%
Nave
13%
Vaccination
12%
Cyclophosphamide
12%
Fludarabine
12%
Cyclin D1 (CCND1)
12%
Monoclonal Antibody
12%
Chemoimmunotherapy
10%
Non-responders
10%
Frontline Therapy
10%
Aggressive B-cell Lymphoma
10%
Antibody Response
9%
Remission
9%
Previously Untreated
9%
FDG PET-CT
9%
Chronic Myeloid Leukemia
9%
Transplantation
9%
Unfit Patients
9%
Bruton Tyrosine Kinase Inhibitor
8%
Initial Treatment
8%
Phase II Study
8%
Multicenter Retrospective Study
8%
Serological Response
8%
Small Interfering RNA (siRNA)
8%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Lymphatic Leukemia
76%
Diseases
38%
Ibrutinib
34%
Progression Free Survival
28%
Overall Survival
25%
Chlorambucil
24%
Messenger RNA
24%
Acute Myeloid Leukemia
24%
COVID-19 Vaccine
24%
Obinutuzumab
23%
Venetoclax
18%
Remission
17%
Rituximab
17%
Minimal Residual Disease
15%
Nonhodgkin Lymphoma
14%
Small Interfering RNA
13%
Infection
13%
SARS Coronavirus
12%
Cyclin D1
12%
Monoclonal Antibody
12%
Malignant Neoplasm
9%
Fludarabine
9%
Cyclophosphamide
9%
Protein Tyrosine Kinase Inhibitor
8%
Bruton Tyrosine Kinase Inhibitor
8%
B Cell Lymphoma
8%
Leukemia
8%
Myeloid Leukemia
8%
Solid Lipid Nanoparticle
7%
Second Cancer
7%
Resveratrol
7%
Acute Lymphoblastic Leukemia
7%
Coronavirinae
7%
Mantle Cell Lymphoma
7%
Bevacizumab
7%
Bisantrene
7%
Hodgkin Disease
7%
Nanomedicine
7%
Dasatinib
7%
Phase II Trials
7%
Clinical Trial Results
7%
Brentuximab Vedotin
7%
Philadelphia 1 Chromosome
7%
microRNA 15a
7%
Bendamustine
7%
Zanubrutinib
7%
Retrospective Study
7%
Waldenstroem macroglobulinemia
7%
Polyethylene Terephthalate
7%
Chemotherapy
6%
Medicine and Dentistry
B-Cell Chronic Lymphocytic Leukemia
33%
Non-Hodgkin Lymphoma
29%
Diseases
26%
Ibrutinib
26%
Overall Survival
23%
Positron Emission Tomography-Computed Tomography
22%
COVID-19 Vaccine
14%
B-Cell Lymphoma
14%
Progression Free Survival
13%
Retrospective Study
10%
Tyrosine-Kinase Inhibitor
8%
B Cell
8%
Lymphocyte
8%
Myeloid Leukemia
8%
Systematic Review
7%
Burkitt's Lymphoma
7%
NPM1
7%
Phase II Trials
7%
Humoral Immunity
7%
Observational Study
7%
Fungal Infection
7%
Meta-Analysis
7%
Leukemia Cell
7%
Malignant Neoplasm
7%
Acute Myeloid Leukemia
7%
Dasatinib
7%
Patient-Data
7%
Acute Lymphoblastic Leukemia
7%
Philadelphia 1 Chromosome
7%
Hodgkin's Lymphoma
7%
Brentuximab Vedotin
7%
Chronic Lymphocytic Leukemia
7%
Booster Dose
7%
Mind-Body Interventions
7%
Bruton Tyrosine Kinase Inhibitor
7%
MALT Lymphoma
7%
Large-Cell Lymphoma
7%
Richter's Transformation
7%
Chimeric Antigen Receptor T-Cell Immunotherapy
7%
Rituximab
7%
Bendamustine
7%
Zanubrutinib
7%
Waldenström's Macroglobulinemia
7%
Messenger RNA
7%
Autologous Stem Cell Transplantation
7%
Hematological Cancer
5%
Lymphocyte Antigen Receptor
5%
Cell Therapy
5%
Follicular Lymphoma
5%
Karyotype
5%